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Mammographic screening has led to a markedly increased detec-
tion of ductal carcinoma in situ (DCIS), with 15–20% of all
screen-detected breast cancers being DCIS. Breast-conserving
therapy (BCT) is increasingly employed for these lesions.
Approximately 40–60% of all patients with DCIS are currently
offered conservative treatment (Ernster et al, 1996). BCT carries
the risk of recurrent disease, which can be the result of outgrowth
of the same disease, or represent a new primary tumour. The local-
ization of the recurrence is mainly used to distinguish between
these two events. Outgrowth of the same disease (= residual
disease) occurs at or near the site of the primary DCIS, whereas
lesions developing in another quadrant may be considered new
primary tumours. Morphological comparison of the initial tumour
with the recurrence may help to distinguish between residual and
new disease. Several studies have shown that there is a significant
correlation between the histological type of DCIS component
adjacent to an invasive carcinoma and the grade of the invasive
breast cancer, with well differentiated DCIS being associated with
grade I invasive breast cancer, and poorly differentiated DCIS with
grade III invasive carcinoma (Lampejo et al, 1994; Goldstein and
Murphy, 1996). Therefore, it is likely that if progression from in
situ to invasive carcinoma occurs, well differentiated DCIS gives
rise to grade I invasive carcinoma, whereas poorly differentiated
DCIS gives rise to grade III invasive breast cancer. Different
morphology between the primary and the recurrent tumour may be
due to the occurrence of a new neoplasm, or due to loss of differ-
entiation features, further referred to as ‘dedifferentiation’. It is a
matter of debate whether dedifferentiation is a common phenom-
enon in breast cancer development. A study focusing on histolog-
ical progression in invasive breast cancer showed a high rate of
similarity between the grade of the primary invasive lesion and the
subsequent local, nodal or distant recurrence (Millis et al, 1998),
suggesting that dedifferentiation is not very likely to occur in
breast cancer. No study has investigated progression of DCIS
treated with BCT. 
We compared localization and histological type of the primary
DCIS with the local recurrence in a series of patients treated with
BCT for DCIS in the European Organization for Research and
Treatment of Cancer (EORTC) trial 10853 (Julien et al, 2000). To
support the histological classification, immunohistochemistry was
used to assess the expression of oestrogen receptor (ER), proges-
terone receptor (PR), p53 and HER2/neu (c-ErbB2) proteins in the
primary DCIS and the recurrence. Well differentiated DCIS and
grade I invasive breast cancer are often immuno-positive for ER
and PR, whereas poorly differentiated DCIS and grade III invasive
breast cancer frequently overexpress HER2/neu and p53 (Bobrow
et al, 1994; Zafrani et al, 1994; Leal et al, 1995; Perin et al, 1996;
Mack et al, 1997). 
The objectives of this study were to obtain insight into the
incidence of second primary tumours after BCT for DCIS and to
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occurs. 
MATERIALS AND METHODS 
Patients 
Histological slides and tissue blocks were collected of patients
who were randomized in the EORTC trial 10853 and who devel-
oped a local recurrence. Study design, eligibility criteria, treat-
ment, follow-up procedures and definition of endpoints have been
described in detail in a report on the first results of the trial (Julien
et al, 2000). In this study, 1010 patients had been randomized; at
the time of the collection of the material for the current study, 145
recurrences had occurred, half of which were invasive breast
cancers. Information about the localization of primary DCIS and
local recurrence was obtained from the EORTC Data Center. 
Histology 
Slides were collected of 120 of the 145 local recurrences (83%)
and were reviewed by one of the authors (JLP), without know-
ledge of the histological type of the primary lesion. Since the
corresponding primary lesion of 116 of the 120 cases had been
reviewed previously by the same pathologist as part of a central
pathology review for 863 of the randomized cases, histology of the
primary lesion and recurrence of these cases could be compared. 
DCIS was classified according to the classification described by
Holland et al (1994), based on cytonuclear morphology and on
architectural patterns, subdividing the lesion into well, intermedi-
ately, and poorly differentiated DCIS. Invasive recurrences were
classified according to the standard WHO criteria (World Health
Organisation, 1981), and graded according to the Bloom and
Richardson criteria, modified by Elston and Ellis (1991). 
Immunohistochemistry 
For 71 patients the blocks of both the primary DCIS and the recur-
rence could be collected. Immunohistochemistry was performed
on 4 mm-thick sections of formalin-fixed, paraffin-embedded
tissues. The sections were mounted on Apes-coated slides and
dried. After the sections were dewaxed and endogeneous perox-
idase was blocked using 3% hydrogenperoxidase/methanol for 20
minutes, slides were washed in running demi water for 5 minutes.
Sections were preincubated for 30 minutes at room temperature
(RT) in 1% BSA/PBS (ER, PR) or 5% NGS/PBS (HER2/neu,
p53). For immunostaining of ER, PR and p53, antigen retrieval
was done by boiling for 15 minutes in 10 mM citrate buffer (pH6)
in a microwave oven. ER staining was performed using the mono-
clonal antibody ER1D5, with a dilution of 1:500 (Immunotech,
Marseille, France). PR staining was performed using the poly-
clonal antibody rabbit anti-human PR at a dilution of 1:800
(DAKO, Glostrup, Denmark). HER2/neu staining was performed
using the monoclonal antibody 3B5, at a dilution of 1:10 000 (Van
de Vijver et al, 1988). p53 protein staining was performed using
the monoclonal antibody DO-7, at a dilution of 1:8000 (DAKO).
Primary antibodies were diluted in 1% BSA/PBS. The sections
were incubated with the primary antibody overnight at 4˚C. After
washing in PBS, the slides were incubated with biotinylated goat
anti-mouse or -rat immunoglobulins (DAKO), diluted to 1:500 in
10% NHS/BSA/PBS, and subsequently with peroxidase-conjugated
streptavidin (StreptABComplex/HRP, DAKO), diluted to 1:200 in
0.25% NGS/BSA/PBS, both for 30 minutes at RT. Peroxidase
activity was detected by incubation for 5 minutes at RT with 3-3¢-
diamino-benzidine tetrahydrochloride (DAB), producing a brown
staining reaction. Sections were counterstained with haema-
toxylin. Stainings of the primary lesion and the recurrence were
done in pairs in one run, to avoid differences due to technical arte-
facts. 
The immunohistochemical staining was assessed by one patho-
logist (MvdV), in independent sessions for the primary lesions and
recurrences. In those recurrences where both a DCIS and an invas-
ive component were present, these were scored separately. 
ER and PR status and HER2/neu overexpression were analysed
as negative versus any positive staining. For p53 an estimate of
the percentage of positive tumour cell nuclei was given using a 
6-point scale (0 = 0%, 1 = < 10%, 2 = 10–25%, 3 = 25–50%, 4 =
50–75%, 5 = 75–100%). The mean staining intensity was deter-
mined using a 4-point scale (0 = none, 1 = weak, 2 = moderate, 3 =
strong). The staining score was calculated as the sum of the mean
staining intensity and the percentage of positive tumour cell nuclei
(range 0–8). A score of 0 to 4 was determined p53-negative and a
score of equal to or greater than 5 was determined p53-positive. 
Positive and negative controls were included in every run.
Tumours with known expression of ER, PR, p53 and/or HER2/neu
were used as positive controls. Normal breast tissue (present in
most cases) served as an internal control for ER and PR stainings. 
In some cases the amount of tumour in the block was insuffi-
cient for staining of all 4 markers, therefore the results of 4 pairs
for ER, 5 for PR, 4 for HER2/neu, and 2 for p53 immunostaining
are not included. 
Statistical analysis 
Spearman’s ranked correlation was used to evaluate the relation
between the histological type of the primary DCIS and the recur-
rence. The strength of correlation was determined by the weighted
kappa statistic. The simple kappa statistic was used for the correla-
tion of the marker expression of the primary and recurrent lesion,
since here there are only two values for each marker. Values of
kappa range from 0 for chance agreement only to +1 for perfect
correlation. A kappa value of 0 to 0.20 indicates a weak correla-
tion, 0.21 to 0.40 fair, 0.41 to 0.60 moderate, 0.61 to 0.80 good,
and 0.81 to 1.00 a very good correlation (Altman, 1997). 
RESULTS 
61 of the 116 recurrences were DCIS (53%) and 55 were invasive
(47%). 44 patients (38%) had been treated with excision followed
by radiotherapy (25 DCIS, 19 invasive recurrences), and 72
patients by excision only (62%) (36 DCIS, and 36 invasive recur-
rences). The median time to recurrence was 36 months (range, one
to 146 months); the median time to a DCIS recurrence was 26
months and to an invasive recurrence 41 months. 13 of the 116
recurrences (11%) occurred in a different quadrant to the primary
DCIS; all other recurrences were located at or near the site of the
original excision. 
Histology 
The histological type of the primary DCIS was well differentiated
in 26 (22%), intermediately differentiated in 33 (29%) and poorly
540 N Bijker et al 
British Journal of Cancer (2001) 84(4), 539–544 © 2001 Cancer Research Campaigndifferentiated in 57 (49%) cases. Of the 55 invasive recurrences,
49 were invasive ductal, 2 invasive lobular, one mixed ductulo-
lobular and 3 mucinous carcinomas. 
41 of the 55 invasive recurrences had an associated DCIS
component. The mean diameter of the invasive carcinomas was 12
mm (range, 1 to 30 mm); the size of the invasive recurrence was
not significantly different for those recurrences whose primary
DCIS was well, intermediately or poorly differentiated. 
There was a moderate correlation between the histological type
of the primary and the recurrent DCIS (kappa = 0.56, Table 1A),
the correlation between the primary DCIS and the invasive recur-
rence was weaker (kappa = 0.33, Table 1B). 
Of 61 DCIS recurrences, 43 (70%) were of identical histological
type compared with the primary DCIS. The grade of the invasive
recurrence matched with the histological type of the primary DCIS
in 29 cases (53%). Of note, one poorly differentiated DCIS, and 3
grade III invasive carcinomas developed after a well differentiated
primary DCIS. Furthermore, one well differentiated DCIS, and 4
grade I invasive carcinomas developed after a poorly differentiated
DCIS. All these recurrences occurred in the same quadrant as the
primary lesion. 
Two of the 17 invasive recurrences (12%) after well differenti-
ated DCIS were axillary lymph node positive, 5 of the 14 (36%)
after intermediately differentiated DCIS, and 11 of the 24 (46%)
after poorly differentiated DCIS. None of the 3 grade III invasive
recurrences after well-differentiated DCIS were lymph node
positive. 
When DCIS and invasive recurrences are taken together, 72
(62%) had the same histological type/grade as the primary DCIS.
In the invasive recurrences, the grade of the infiltrating tumour
was compared with its associated DCIS component: none of the
grade III invasive carcinomas had an associated well differentiated
DCIS, and vice versa. 
Immunohistochemistry 
40 of the 71 recurrences on which immunohistochemical staining
was performed were DCIS (56%) and 31 were invasive (44%). 27
patients (38%) had been treated with excision and radiotherapy,
and 44 (62%) by excision only. Table 2 shows the association
between the histological type and the marker expression of the
primary DCIS. Well differentiated DCIS was associated with ER
and PR immuno-positivity; poorly differentiated DCIS was related
with HER2/neu and p53 overexpression. 
Table 3 shows the marker expression of the primary DCIS related
to the recurrence. For ER, HER2/neu and p53 there was a good to
very good correlation, for PR the correlation was moderate. 
In 36 of 57 cases (63%) for which ER, PR, HER2/neu and p53
could all be immunostained, the marker expression of the primary
DCIS was identical to that of the recurrence. 
The cases with a difference in the histological type and/or in the
marker expression are listed in Table 4. In only 5 cases (9%) more
than one marker differed in its expression. 
When ER or PR expression changed from negative to positive,
or when HER2/neu or p53 expression changed from positive to
negative, recurrent lesions can be considered a second primary
tumour, which was the case in 22 lesions. In only one case all
markers differed (case 31, Table 4). This patient developed well
differentiated DCIS after poorly differentiated DCIS, which is
therefore likely to be a second primary lesion, even though it
occurred in the same quadrant. 
9 of 71 recurrences showed dedifferentiation with respect to
marker expression, i.e. loss of ER or PR immuno-positivity or gain
of HER2/neu or p53 overexpression. In only one recurrence (case
39) the histological type of the lesion and the marker expression
both changed toward a more dedifferentiated lesion. In the other
cases, either the histology between the primary and recurrent
lesion differed and the marker expression was identical (15 of 26
cases (58%)), or the marker expression differed and the histology
was the same (14 of 25 cases (56%), Table 4). 
In 25 of 57 cases (44%) for which histology and marker expres-
sion were both completely evaluated, the primary and recurrent
lesion had identical histology and marker expression. 
Case 15, with a poorly differentiated DCIS recurrence devel-
oping after a well differentiated DCIS, had identical marker
expression in the two lesions. In case 35, with a grade III invas-
ive carcinoma after a well differentiated DCIS, PR expression
changed from negative to positive. 
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Table 1A Histological type primary DCIS related to histological type
recurrent DCIS 
DCIS recurrence 
Well Intermediate Poor Total 
Primary DCIS Well 5 3 1 9 
Intermediate 3 8 8 19 
Poor 1 2 30 33 
Total 9 13 39 61 
Spearman Correlation 0.65. Weighted Kappa 0.56 (95% CI 0.38–0.73). 
Table 1B Histological type primary DCIS related to grade invasive
recurrence 
Grade invasive recurrence 
I II III Total 
Primary DCIS Well 8 6 3 17 
Intermediate 3 7 4 14 
Poor 4 6 14 24 
Total 15 19 21 55 
Spearman Correlation 0.38. Weighted Kappa 0.33 (95% CI 0.13–0.54). 
Table 2 Histological type related to marker expression primary DCIS 
ER PR HER2/neu p53 
N positive (%) N positive (%) N positive (%)  N positive (%)
Primary DCIS Well 13/13 (100) 9/13 (69) 1/12 (8) 1/13 (8) 
Intermediate 17/21 (81) 13/20 (65)  5/19 (26) 3/21 (14) 
Poor 14/36 (39) 10/35 (29) 24/34 (71) 10/36 (28) All 5 immunohistochemically analysed lesions that had recurred
in another quadrant showed either the same histology or identical
marker expression compared with the primary lesion (Table 4). 
An effect of radiotherapy on the change of histological type or
marker expression in the recurrent lesion could not be observed
(data not shown). 
DISCUSSION 
In this study we have analysed primary DCIS and their recurrences
after breast-conserving therapy in patients treated as part of a
randomized clinical trial (EORTC 10853). The main goals of this
study were to obtain insight into the incidence of second primary
tumours and to investigate whether ‘dedifferentiation’ from well
to poorly differentiated cancers occurs. 
11% of the recurrences developed in a different quadrant to the
primary lesion. Clinically, this suggests that these cases are second
primary tumours. However, neither by morphology nor by
immunohistochemistry was support found that these recurrences
were new primary lesions. Establishing the relation between the
542 N Bijker et al 
British Journal of Cancer (2001) 84(4), 539–544 © 2001 Cancer Research Campaign
Table 3 Marker expression of primary DCIS related to recurrence 
Primary DCIS Recurrence Kappa (95% CI) 
Positive Negative
ER positive 40 1 
negative 2 23 0.90 (0.80–1.01) 
PR positive 24 8 
negative 8 26 0.54 (0.33–0.74) 
HER2/neu positive 24 7 
negative 1 33 0.75 (0.60–0.91) 
p53 positive 9 5 
negative 0 55 0.74 (0.53–0.95) 
CI = confidence interval. 
Table 4 Cases listed in which marker expression and/or histology of primary DCIS was not identical to recurrence 
Primary DCIS Recurrence 
Patient Histological type ER PR HER2 p53  Quadrant Histological type Grade invasion ER PR HER2 p53 
Histology similar, markers different 
1 well + – – – same well + + – – 
2 poor + + – + other poor –  – – + 
3 poor – – – – same poor – + –  –
4 intermediate + + – + same intermediate + – – – 
5 poor + – + + same poor + – – + 
6 poor + + + – same poor + – + – 
7* well + – – – same well + – – 
8* poor + + – – other poor +
9 poor – – + – same poor 3 – – – – 
10 intermediate + + – – same intermediate 2 + – – – 
11 intermediate + + – – same intermediate 2 + – – – 
12 poor + – – – same poor 3 + + – – 
13 poor – – + – same 3 + – + – 
14 intermediate + + + – other 2 + + – – 
Markers similar, histology different 
15 well + + – – same poor + + – – 
16 poor – – + – same intermediate – – + – 
17 intermediate + + – – same well + + – – 
18 intermediate + + – – same well + + – – 
19 intermediate + + – – same poor + + – – 
20* intermediate – – + same poor – – + 
21* intermediate + + – – same poor – – 
22 intermediate + + – – other intermediate 1 + + – – 
23 well + + – – other intermediate 1 + + – – 
24 well + + – – same intermediate 1 + + – – 
25 poor + + – – same intermediate 3 + + – – 
26* poor + – – same intermediate 2 + – – – 
27* poor – – + same intermediate 3 – – + 
28 intermediate + + – – unknown 3 + + – – 
29* intermediate + – – same 3 + + – – 
Histology and markers different 
30 intermediate + – – – same poor + + – – 
31 poor – – + + same well + + – – 
32 intermediate – – + – same poor – – – – 
33 intermediate + + + – same poor + + – – 
34* intermediate + + – – unknown intermediate 1 – – – 
35* well + – – same poor 3 + + – – 
36 poor + + + + same poor 2 + + + – 
37 well + + + – same intermediate 2 + + – – 
38 poor + – – – same poor 2 + + – – 
39 well + + – – same 2 + – – – 
40 well + + – + same 2 + – – – 
+ = positive expression; – = negative expression; * = not all markers scored. Histology and markers in primary DCIS and its local recurrence 543
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recurrence and the primary lesion by clinical comparison of the
localization of the two lesions is difficult, especially when there is
apparently no anatomical relation between the two. DCIS grows
typically unicentric, and spreads along one of the 15–20 branching
trees forming the glandular breast tissue. These trees are anatomi-
cally ill-defined, and often exceed the borders of a quadrant. This
may give rise to recurrences remote from the primary lesion, still
developing in the same tree, thus being outgrowth of residual
disease. 
We observed 5 patients with a well differentiated DCIS recurrence
or grade I invasive carcinoma evolving after a poorly differentiated
DCIS. Although all these recurrences occurred at the same quadrant
as the primary DCIS, it is likely that these cases are second primary
tumours based on the different histology. In fact, in one of these cases
the marker expression analysis showed that the status of ER and PR
turned from negative to positive, and the overexpression of p53 and
HER2/neu from the primary lesion was lost in the recurrence, which
is consistent with the morphological alteration. Alternatively, by
incomplete eradication of the rarely observed histologically hetero-
geneous tumours, the well differentiated component may have been
left behind (Goldstein and Murphy, 1996). 
Our findings show concordant histology in 62%, and identical
marker expression in 63% between the primary DCIS and the invas-
ive or non-invasive recurrence. These results suggest that the
majority of recurrences after BCT for DCIS reflect residual disease.
When both could be scored, the histology and marker expression in
primary DCIS and local recurrence was identical in 44%. 
It has not been resolved whether dedifferentiation in breast
cancer is a common phenomenon, and thus whether a well differ-
entiated DCIS can recur as a higher grade lesion. 
A considerable number of recurrent lesions differed one grade
from the primary DCIS, resulting in a higher-grade recurrence (i.e.
grade II invasive carcinoma after a well-differentiated DCIS), but
also frequently in a lower-grade recurrence (i.e. those with an
intermediately differentiated recurrence after a poorly differenti-
ated DCIS). We do not believe such differences to be signs of
dedifferentiation or new tumour development, but as an expression
of the weakness of the three-tier classification system of DCIS.
Inter-observer variability in classifying DCIS is a well-known
problem (Sloane et al, 1998). Especially for intermediately differ-
entiated DCIS, low consistency is usually obtained. Inter-observer
variation in classification of the extremes occurs less frequently,
because these are easier to recognize. When this is taken into
account, the observed differences are less evident. 
4 patients developed a poorly differentiated DCIS or a grade III
invasive carcinoma after a well differentiated DCIS. In these cases
progression might have occurred, although in two of these cases the
marker expression did not confirm this progression towards a
higher grade. In both, the marker expression of the recurrence was
consistent with the primary well differentiated DCIS (ER/PR posi-
tive, HER2/p53 negative). In the other two cases, the marker
expression could not be evaluated. Also, the axillary lymph node
status was negative in all 4 recurrences. In only one other recur-
rence, both the histological type and the marker expression
changed towards a higher-grade lesion. 
If well-differentiated DCIS frequently progressed to grade III
recurrences, this would be a reason for more aggressive treatment for
this type of lesion. However, although dedifferentiation can occa-
sionally occur, it was an uncommon phenomenon in our study. 
Other techniques investigating the relation between primary and
recurrent breast malignancies have been described recently. In a
study investigating loss of heterozygosity (LOH) in 3 cases of
DCIS and their local DCIS recurrences a high concordance has
been demonstrated between the lesions, although genetic progres-
sion was shown in all 3 by additional LOH in the recurrent lesion
(Lininger et al, 1998). More recently, a high concordance in chro-
mosomal alterations in 17 of 18 cases of initial DCIS and their
subsequent DCIS recurrences was shown with comparative
genomic hybridization (CGH), indicating a clonal relationship
between the two events (Waldman et al, 2000). However, the
investigators also found a small, but statistically significant,
increase in the number of genetic alterations in the recurrences,
suggesting dedifferentiation. 
The grade of invasive breast carcinoma has been shown to be an
independent prognostic factor for recurrence and survival (Elston
and Ellis 1991). Gupta et al (1997) have shown that the histolo-
gical type of DCIS, in the presence of an invasive tumour, corre-
lates with the clinical outcome of the patient. If the histological
type of the primary DCIS correlates with the grade of the subse-
quent invasive recurrence, the histological type of DCIS is also
likely to have prognostic implications, with a higher risk of a more
aggressive behaviour of local recurrence after poorly differenti-
ated compared to local recurrence after well differentiated DCIS. 
Our results on basis of histology and marker expression
contribute to obtain insight into the type of recurrence after BCT
for DCIS. Comparison of genetic alterations between the primary
tumours and their invasive and non-invasive recurrences will help
to further define these lesions in order to offer optimal clinical
treatment of the various subtypes of DCIS. 
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